Early Prevention of Polycystic Ovarian Syndrome (PCOS) Risk In Children with Growth Hormone Deficiency
DOI:
https://doi.org/10.55175/cdk.v48i11.146Keywords:
growth hormone deficiency, PCOS, Growth hormone, polycystic ovarian syndromeAbstract
Polycystic ovarian syndrome (PCOS) is a hormonal disorder and is the leading cause of infertility in women. In 2012, World Health Organization (WHO) stated that around 116 million women around the world were affected by PCOS. The etiology of PCOS has not been fully understood. The most known risk factors are obesity and insulin resistance, usually found in children with growth hormone deficiency (GHD). Growth hormone (GH) therapy can hopefully be the solution to growth disorder and prevent PCOS risks. This article will discuss PCOS and the role of GHD therapy on children in preventing PCOS.
Polycystic Ovarian Syndrome (PCOS) adalah gangguan hormonal yang paling umum ditemukan dan merupakan penyebab utama infertilitas pada perempuan. World Health Organization (WHO) pada tahun 2012 menyatakan sekitar 116 juta wanita di seluruh dunia menderita PCOS. Etiologi PCOS belum sepenuhnya dipahami. Namun, faktor risiko yang paling umum diketahui adalah obesitas dan resistensi insulin yang sering didapatkan pada anak-anak dengan growth hormone deficiency (GHD). Terapi growth hormone (GH) diharapkan dapat mengatasi masalah pertumbuhan dan mencegah risiko PCOS. Artikel ini akan membahas PCOS dan peran terapi GHD dalam pencegahan PCOS pada anak.
Downloads
References
Perkumpulan Obstetri dan Ginekologi Indonesia (POGI). Konsensus tata laksana sindrom ovarium polikistik. Jakarta; 2016.
Zeng X, Xie Y, Liu Y, Long S, Mo Z. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clinica Chimica Acta.2020;502:214-21.
Ollila MME, West S, Keinänen-Kiukaanniemi S, Jokelainen J, Auvinen J, Puukka K, et al. Overweight and obese but not normal weight women with PCOS are at increased risk of type 2 diabetes mellitus - A prospective, population-based cohort study. Hum Reprod. 2017;32(2):423–31.
Yedulapuram S, Gunda M, Moola N, Kadarla R. An overview on polycystic ovarian syndrome. Asian Journal of Pharmaceutical Research and Development. 2019;7(4):72-80.
Wolf W, Wattick R, Kinkade O, Olfert M. Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. International Journal of Environmental Research and Public Health. 2018;15(11):2589.
Okoroh E, Hooper W, Atrash H, Yusuf H, Boulet S. Prevalence of polycystic ovary syndrome among the privately insured, United States, 2003-2008. American Journal of Obstetrics and Gynecology. 2012;207(4):299.1-299.7.
Sumapraja K, Pangastuti N. Profile of polycystic ovarian syndrome patients in Dr. Cipto Mangunkusumo General Hospital Jakarta March 2009 - March 2010. Indonesian Journal of Obstetrics and Gynecology 2011;35(1):8-12.
Hoffman B. William's gynecology. 3rd ed. New York: McGraw-Hill Education; 2016.
De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: An update. Reprod Biol Endocrinol. 2016;14(1):1–17.
Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467–520.
The Rotterdam ESHRE/ASRM‐sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related topolycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-7
Tharian K, Warner J. Polycystic ovarian syndrome in adolescent girls. Paediatr Child Heal (United Kingdom). 2015;25(7):319–24.
De Melo AS, Dias SV, De Carvalho Cavalli R, Cardoso VC, Bettiol H, Barbieri MA, et al. Pathogenesis of polycystic ovary syndrome: Multifactorial assessment from the foetal stage to menopause. Reproduction 2015;150(1):11–24.
Gjerstad JK, Lightman SL, Spiga F. Role of glucocorticoid negative feedback in the regulation of HPA axis pulsatility. Stress 2018;21(5):403–16.
Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: Pathophysiology, presentation, and treatment with emphasis on adolescent girls. J Endocr Soc. 2019;3(8):1545–73.
Bellver J, Rodríguez-Tabernero L, Robles A, Muñoz E, Martínez F, Landeras J, et al. Polycystic ovary syndrome throughout a woman’s life. J Assist Reprod Genet. 2018;35(1):25–39.
Ipsa E, Cruzat V, Kagize J, Yovich J, Keane K. Growth hormone and insulin-like growth factor action in reproductive tissues. Frontiers in Endocrinology. 2019;10:777.
Oberbauer AM. Developmental programming: The role of growth hormone. J Anim Sci Biotechnol. 2015;6(1):1–7.
Brinkman JE, Tariq MA, Leavitt L, Sharma S. Physiology, growth hormone [Internet]. 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482141/
Aguirre GA, Ita JR, Garza RG, Castilla-Cortazar I. Insulin-like growth factor-1 deficiency and metabolic syndrome. J Transl Med. 2016;14(1):1–23.
Kim SH, Park MJ. Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab. 2017;22(3):145–52.
Braun L, Marino R. Disorders of growth and stature. Pediatrics in Review. 2017;38(7):293-304.
Shalitin S, Kiess W. Putative effects of obesity on linear growth and puberty. Horm Res Paediatr. 2017;88(1):101–10.
Chinoy A, Murray PG. Diagnosis of growth hormone deficiency in the paediatric and transitional age. Best Pract Res Clin Endocrinol Metab. 2016;30(6):737–47.
Batubara JR, Aditiawati, Tjahjono HA. Penggunaan hormone pertumbuhan pada anak dan remaja di Indonesia. IDAI. 2017;1(1):1–50.
Blum WF, Alherbish A, Alsagheir A, El Awwa A, Kaplan W, Koledova E, et al. The growth hormone-insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders. Endocr Connect. 2018;7(6):212–22.
Grimberg A, DiVall SA, Polychronakos C, Polychronakos C, Allen DB, Cohen LE, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: Growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. 2017;86(6):361–97.
Murray PG, Dattani MT, Clayton PE. Controversies in the diagnosis and management of growth hormone deficiency in childhood and adolescence. Arch Dis Child. 2016;101(1):96–100.
Stanley TL, Grinspoon SK. Effects of growth hormone–releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Hormone & IGF Research 2015;25(2):59–65. doi:10.1016/j.ghir.2014.12.005
Baronio F, Mazzanti L, Girtler Y, Tamburrino F, Fazzi A, Lupi F, et al. The influence of growth hormone treatment on glucose homeostasis in growthhormone-deficient children: A six-year follow-up study. Horm Res Paediatr. 2016;86(3):196–200.
Deodati A, Cianfarani S. The rationale for growth hormone therapy in children with short stature. J Clin Res Pediatr Endocrinol. 2017;9(2):23–32.
Ahmid M, Perry CG, Ahmed SF, Shaikh MG. Growth hormone deficiency during young adulthood and the benefits of growth hormone replacement. Endocr Connect. 2016;5(3):1–11.
Smuel K, Kauli R, Lilos P, Laron Z. Growth, development, puberty and adult height before and during treatment in children with congenital isolated growth hormone deficiency. Growth Horm IGF Res. 2015;25(4):182–8.
Collett-Solberg PF, Jorge AAL, Boguszewski MCS, Miller BS, Choong CSY, Cohen P, et al. Growth hormone therapy in children; Research and practice – A review. Growth Horm IGF Res. 2019;44:20–32.
Richmond E, Rogol AD. Treatment of growth hormone deficiency in children, adolescents and at the transitional age. Best Pract Res Clin Endocrinol Metab. 2016;30(6):749–55.
Pfäffle R. Hormone replacement therapy in children: The use of growth hormone and IGF-I. Best Pract Res Clin Endocrinol Metab. 2015;29(3):339–52.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Cermin Dunia Kedokteran
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
